FormWeb • trastuzumab

Henry Ford Health

Approved Hospital Formulary

FormWeb QuickStart Questions or Suggestions? Pharmacy Intranet

Add Formweb to your mobile device

Brand name products with an equivalent generic may not be available to order at Henry Ford Health. For questions, contact inpatient pharmacy.

Henry Ford Health

Approved Hospital Formulary

FormWeb QuickStart Questions or Suggestions? Pharmacy Intranet

Search results for:

trastuzumab

trastuzumab

Drug Name	Form	Strength
Kanjinti	INJECTION, INTRAVENOUS	150 mg SDV and 420 mg MDV
Herceptin	POWDER FOR INJECTION, INTRAVENOUS	150 mg SDV
Trazimera	POWDER FOR INJECTION, INTRAVENOUS	150 mg SDV and 420 mg MDV

VIEW MORE antineoplastics, HER2 inhibitors
CLASS

High Alert Drug : Policy

	Generic Name	Brand Name
Biosimilar (HFH preferred)	trastuzumab-qyyp	Trazimera
Biosimilar (approved alternate)	trastuzumab-anns	Kanjinti
Originator product	trastuzumab	Herceptin

Last updated: Mar. 8, 2024

Biosimilar Tier 1: Use of Biosimilars at Henry Ford Health System
Black Box Warning Cardiomyopathy; infusion reactions, pulmonary toxicity; teratogenicity
Look Alike Sound Alike Do Not Confuse trastuzumab with ado-trastuzumab emtansine

This site is intended for the staff of Henry Ford Health.
While others may view accessible pages, Henry Ford Health makes no warranty, express or implied,
as to the use of this information outside of Henry Ford Health.